MedTrace Logo

Influenza Viral Challenge Study of CC-42344 in Healthy Participants

NCT06160531 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-08-05

No results posted yet for this study

Summary

Participants in this study will be given either CC-42344 (one of two dose levels) or placebo orally for 5 days after receiving an influenza (flu) challenge virus. Participants will not know whether they are getting placebo or CC-42344. The amount of virus in nasal samples will be measured over time. Side effects and pharmacokinetics (the amount of CC-42344 in blood) will also be measured.

Conditions

Interventions

DRUG

CC-42344

Anti-influenza A agent

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • hVIVO Services Limited

    collaborator INDUSTRY

  • Cocrystal Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Victoria Parker, MMBS · hVIVO Services Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-25
Primary Completion
2024-05-03
Completion
2024-07-18

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06160531 on ClinicalTrials.gov